Introduction
The SAH gene (SAH: human chromosome 16p12.3) (http://www.ensembl.org/Homo_sapiens/geneview?gene ENSG00000005187) and cDNA (1, 2) were discovered on the basis of the overexpression of its rat homologue (Sah) in kidneys of genetically hypertensive rats (3) . Although the genomic region that houses Sah was initially linked to hyper-
The results of our earlier study on a PstI restriction fragment length polymorphism (RFLP) in SAH, however, suggested that SAH may play a role in body weight in Caucasian hypertensives (12) . Moreover, the Sah locus has been linked to body weight in hypertensive rats (13, 14) . In spontaneously hypertensive rats (SHR), the liver displays increased Sah mRNA (3), but in the brain and testis Sah mRNA is reduced (3, 15) . Such tissue-specific differences have been shown to be determined primarily by SAH genotype (15) . Thus, any action of a SAH variant on body weight in humans could involve hepatic, renal, or other effects. The SAH protein is probably secreted, judging by the presence of a signal peptide that has the ability to target it to the secretory compartment of the cell. However, its function has not been investigated. Nevertheless, the SAH protein shares homology with a number of metabolic enzymes, including bacterial acetylcoenzyme A (CoA) synthetase (1), and acyl-CoA ligases (14) , such as bovine xenobiotic-metabolizing medium-chain fatty acid (MCFA): CoA ligase (16) . The SAH product also demonstrates acyl-CoA synthetase activity for MCFA (17) . Part of the acetyl-CoA produced during MCFA oxidation is directed to de novo synthesis of long-chain fatty acids (LCFAs), which are then incorporated into triglyceride or other complex lipids (18, 19) . SAH could thus play a role in lipid metabolism.
SAH of both humans and rats contains putative mitochondrial and peroxisome targeting sequences, together with amino acid characteristics that are consistent with a peroxisomal location (14) . The SAH protein could thus be a peroxisomal and/or mitochondrial enzyme, possibly involved in lipid metabolism (14) .
The aim of the present study was to perform association analyses of several more recently discovered polymorphisms in SAH and its promoter in order to examine their relationship with hypertension and overweight in white hypertensive patients.
Methods

Subjects
Subjects were white Anglo-Celtic Australians. The 121 hypertensives (HTs) were the offspring of parents who both had hypertension, and the 178 normotensives (NTs) had parents who were both normotensive past the age of 50 years. Ascertainment details have been described previously (20) . The study was approved by the University of Sydney Ethics Committee and the subjects gave informed consent. Demographic parameters of the subjects are shown in Table 1 . These subjects were, moreover, shown to be capable of demonstrating associations with hypertension (21, 22) and with overweight (23, 24) should these be present. Our use of only HTs with 2 hypertensive parents enhanced the biological power of the study, by increasing the genetic component and so improving the likelihood of detecting any genetic effect that might exist. Based on a frequency of HT of 20% in the adult population, such selection also meant that the HTs were drawn from a general population of HTs ten times larger than the actual cohort size (i.e., 121 10 1,210).
Genotyping
DNA was isolated from whole blood using a QIAamp Mini Kit (Qiagen, Hilden, Germany). Genotype determination was performed for 3 polymorphisms identified by two of the authors (N.I. and K.I.): 1) a 5-base (TTTAA) insertion/deletion polymorphism located 1,037 bp upstream of the SAH transcription start site; 2) an insertion/deletion polymorphism involving two Alu-like sequences in intron 1; and 3) an intron 12 A G single nucleotide polymorphism (SNP) positioned 7 bp upstream of exon 13. 
Promoter Variant
The SAH insertion/deletion variant at 1037 was genotyped by the TaqMan TM system (PE Applied Biosystems, Foster City, USA) as described previously (17) .
Intron 1 Variant
Genotypes for the SAH intron 1 variant were determined by sequential polimerase chain reactions (PCRs), the first involving primers: sense-1, 5 -GACCGGTTTAAGAAATGA CGTGCAG-3 ; antisense-1, 5 -GGATTGGGTACAGAGGG AACTACC-3 (synthesized by Nihon Sejan Corp., Nagano, Japan). After an initial denaturation step at 94°C for 5 min, 30 cycles of 94°C for 1 min, 59°C for 1 min, and 72°C for 1.5 min were performed using a 10 µl reaction mixture that contained 100 ng genomic DNA, 0.25 pmol each primer, 0.1 mmol/l each dinucleotide triphosphates (dNTP), 0.1 U AmpliTaq TM DNA polymerase (Perkin Elmer, Norwalk, USA), 50 mmol/l KCl, 10 mmol/l Tris-HCl, pH 8.3, and 1.5 mmol/l MgCl2. PCR products of 1,200 bp (A allele), 1,500 bp (B and C alleles), and 1,800 bp (D allele) were seen after 3% agarose gel electrophoresis. Samples that had a 1,500 bp band were amplified by a second PCR. This used primers sense-1 and antisense-1 and two other primers, viz., sense-2, 5 -GTGGGCAGCTTTGAGACTAGA GGTG-3 and antisense-2, 5 -CCCAAAGCACTAGGATT ACAGGTG-3 (synthesized by Nihon Sejan Corp.) in the following combinations: sense-1 and antisense-2, and sense-2 and antisense-1. This distinguished between the 1,500 bp B and C alleles. The PCR involved an initial denaturation step at 94°C for 5 min, followed by 30 cycles of 94°C for 1 min, 59°C for 1 min, and 72°C for 1 min using the reaction mixture described above. The PCR products were electrophoresed on a 3% agarose gel and visualized under ultra violet (UV) light by ethidium bromide staining. This subsequent PCR was able to distinguish alleles B and C, there being a band of 300 bp for allele B, but no band ( 300 bp) for allele C when using sense-1 and antisense-2 primers, and vice versa when using sense-2 and antisense-1. Allele B had been seen in a Japanese population (K.I. and N.I., unpublished), but in our white population it was absent. Of the 3 alleles we did see, allele D was rare (frequency 0.5% in HTs and 1.7% in NTs), so for ease of presentation, data for allele D was combined with that for the minor allele (C). Analyses involving all genotypes observed nevertheless gave similar results to those for combined genotypes.
Intron 12 Variant
The A G SNP was genotyped by the TaqMan TM system (PE Applied Biosystems) as outlined previously (17) .
Statistical Analyses χ
2 and 1-way analysis of variance (ANOVA) were performed using the program StatView (Abacus Concepts, Berkeley, USA). Linkage disequiblium (LD) was tested in the largest group (NTs) by the method of Hill (25) .
Results
Association with Hypertension
Genotype data for each polymorphism are shown in Table 2 . Genotype frequencies did not deviate from Hardy-Weinberg expectations. No significant association with hypertension was seen. The frequency of the minor (G) allele of the intron 12 polymorphism was so low that this variant was not informative. For this reason, analyses were not performed. None of the SAH haplotypes were associated with hypertension (data not shown). For a relative risk of 1.6, our study had 99% power to detect significant association of the SAH promoter variant with hypertension, given the p value we obtained. For the SAH intron 1 polymorphism, the power was 87%. Thus if an association with hypertension existed, we should have been able to detect it.
Association with Overweight
We also examined whether there was any association with overweight. Comparison of the genotypic and allelic data for the SAH intron 1, but not the promoter, variant between overweight HTs (body mass index, BMI 25 kg/m 2 ) and lean HTs (BMI ≤ 25 kg/m 2 ) demonstrated a significant difference (Table 3) .
Linkage Disequilibrium
The two informative polymorphisms (in the promoter and intron 1), together with the PstI RFLP tested previously (12) were tested for LD. The results indicated that the promoter and intron 1 variants were in significant LD, but for the PstI RFLP LD with the other two variants did not reach statistical significance (Table 4) . This is likely to have been due to fact that the rare haplotypes had very low expected frequencies. Much larger numbers would be needed in order to attain significance even in the case of complete LD.
Examination of the genotype-phenotype interaction revealed lower HDL cholesterol for the intron 1 variant in male hypertensives who were homozygous for the major allele: 0.9 0.1 (SEM) mmol/l compared with 1.4 0.2 for other genotypes (F 4.1, p 0.021). Lower total cholesterol of 5.7 0.2 vs. 6.7 0.4 mmol/l (F 3.4, p 0.044), as well as LDL cholesterol of 3.5 0.2 vs. 4.7 0.5 mmol/l (F 6.7, p 0.014), was seen in female hypertensives who were homozygous for the intron 1 major allele. Although these data provide evidence suggesting that genotype has an effect on plasma lipids, these apparent associations were not significant after Bonferroni correction for multiple comparisons.
Discussion
Much as in previous studies that showed a lack of association between a PstI RFLP and HT (12, 26) , the present study of several novel polymorphisms in and near SAH found no association between markers at the SAH locus and HT in a Caucasian Australian population. Linkage studies have also proved negative for the SAH locus and hypertension in French Caucasian (2) and Chinese Asian (27) populations.
The SAH intron 12 A G SNP has been shown to significantly affect BP in Japanese, and this was conveyed through its effects on BMI (17) . We found previously that the frequency of the A2 allele of a diallelic PstI RFLP of SAH was 0.17 in overweight compared with 0.06 in non-overweight HTs ( p 0.011) (12) . In the present study, the frequency of the minor allele of the intron 1 variant was 0.20 in overweight compared with 0.07 in non-overweight HTs ( p 0.013).
The elevation in plasma total and low-density lipoprotein (LDL) cholesterol in subjects possessing one or more copies of the minor allele of the intron 1 variant tested support the association we found with overweight. This may have been due to the possible role of SAH in lipid metabolism through In conclusion, the present study confirms that SAH is not involved in the etiology of hypertension in the Caucasian population studied, but supports a role for SAH in body weight.
